We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Blood Transfusion Practice Wastes Scarce Plasma

By LabMedica International staff writers
Posted on 30 Jul 2013
The use of a blood transfusion protocol in patients with severe trauma is feasible in hospitals, although it is associated with higher waste of plasma.

The protocol, in use since 2007, uses an equal ratio of red blood cells, plasma, and platelets to transfuse patients, yet this 1:1:1 ratio is associated with higher waste of donated blood plasma.

Scientists at the Sunnybrook Health Sciences Center (Toronto, ON, Canada) conducted a randomized trial to determine feasibility and safety of 1:1:1 ratio in 78 patients presenting in a large trauma center, with low blood pressure and substantial bleeding who were expected to need massive blood transfusion. More...
Forty patients were randomly assigned to the fixed-ratio transfusion, and the remaining 38 underwent the laboratory-guided transfusion protocol at the center.

Thawed type AB plasma, a scarce resource, is needed for 1:1:1 transfusion, which also involves delays because of the need to thaw the material. Deaths from all causes after 28 days was higher in the fixed-ratio group at 32.5% compared with 14% in the control group and there was a higher rate of respiratory distress in the patients receiving 1:1:1.


Sandro Rizoli, MD, PhD, a professor of surgery and senior author of the study, said, “These findings suggest that a fixed-ratio transfusion protocol is feasible, but it was associated with increased plasma wastage, about two units per patient”. Widespread adoption of the 1:1:1 strategy has significant resource and safety implications. Its full implementation requires access to thawed type AB plasma, which is chronically in short supply. The 1:1:1 transfusion protocol may lead to unnecessary exposure to blood components and an increased risk of acute respiratory distress syndrome, sepsis, and multiple organ dysfunctions.

The authors concluded that the randomized controlled trial showed the implementation of a fixed-ratio (1:1:1) transfusion protocol was feasible among patients with severe trauma. The full and widespread implementation of such a protocol will challenge blood suppliers because of the increased demand and wastage of plasma. Larger clinical trials are warranted to definitively evaluate the efficacy and safety of transfusion at a 1:1:1 ratio. The study was published on July 15, 2013, in the Canadian Medical Association Journal.

Related Links:
Sunnybrook Health Sciences Center



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The test combines RNA signals from the tumor-immune microenvironment to predict treatment response, rather than relying on a single marker such as PD-L1 expression.(Image Credit: Adobe Stock)

RNA-Based Test Predicts Immunotherapy Response in Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) represents the largest U.S. patient population eligible for immune checkpoint inhibitor therapy. Treatment selection often relies on PD-L1 expression, but a single protein... Read more

Immunology

view channel
Image Credit: Adobe Stock

Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk

A typical pregnancy lasts about 40 weeks, but labor begins prematurely in roughly one in 10 pregnancies. Preterm birth is the leading cause of newborn death worldwide, yet its underlying causes and which... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NeoGenomics selected Indica Labs’ HALO AP platform to eable its digital pathology operations through a scalable, cloud-based framework (Photo courtesy of Indica Labs)

Expanded Partnership Scales AI-Powered Digital Pathology for Oncology

Oncology diagnostics rely on pathology and biomarker information to guide personalized treatment. As computational pathology and artificial intelligence (AI) expand insights from tissue analysis, laboratories... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.